Earnings Material +

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026

Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions

By The Northwire Desk — AI Analysis May 01, 2026 · 02:36 4565

Executive Summary

Nxera Pharma reported Q1 2026 consolidated results showing a net profit of JPY 1,793 million (US$11.4 million), reversing a net loss of JPY 760 million in the prior year period.
Revenue increased to JPY 11,256 million (US$71.7 million), driven by seven R&D milestone events including US$22.5 million from Neurocrine Biosciences and US$10 million from AbbVie.
Eli Lilly announced an agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion; Nxera retains rights to future royalties on the OX2R agonist series and holds an equity stake in Centessa.
Santhera Pharmaceuticals licensing deal for vamorolone (AGAMREE) in Japan/APAC was finalized, with upfront consideration of US$40 million (US$30m cash + US$10m equity).
Cash and cash equivalents decreased to JPY 11,597 million (US$72.6 million) from JPY 20,365 million at the end of FY2025.
R&D expenses decreased by JPY 780 million year-over-year due to streamlined focus and program maturation.

Material Impact

The shift from net loss to net profit is a fundamental improvement in financial health, validating the company's restructuring efforts announced in late 2025.
Revenue growth is heavily reliant on milestone recognition rather than organic product sales alone; while positive, this revenue stream can be lumpy and non-recurring compared to steady commercial sales.
The Eli Lilly/Centessa acquisition validates Nxera's discovery platform (NxWave/NxStaR) but does not directly inject capital into Nxera beyond existing royalty/equity rights.
The significant drop in cash position (approx. JPY 8.7 billion decrease in one quarter despite profitability) is a critical risk factor that requires scrutiny regarding capital allocation or debt servicing.
Regulatory approvals for daridorexant (QUVIVIQ) in Taiwan and MAA submission in South Korea expand the commercial runway, supporting long-term revenue visibility.

4565 · Price

Company Overview

Nxera Pharma is a specialty pharmaceutical company focused on developing innovative medicines, primarily leveraging its GPCR-targeted platforms (NxWave™, NxStaR™).
Flagship commercial product: QUVIVIQ® (daridorexant), a dual orexin receptor antagonist for insomnia, marketed in Japan via Shionogi and expanding to APAC regions.
Other key assets include PIVLAZ® (for rare endocrine disorders) and vamorolone (AGAMREE®) licensed from Santhera for Duchenne Muscular Dystrophy.
Proprietary pipeline includes an oral GLP-1 agonist and multiple GPCR programs in oncology and neurology.

More from